Further, a case report on a patient with advanced cholangiocarcinoma treated with anti-EGFR CART cells combined with anti-CD133 CART cells indicated the safety and feasibility of clinical cancer treatment with CSC-targeted CART cells (Feng et al., 2017). This evidence concerns the gene PROM1 and cholangiocarcinoma.